baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

IMMATICS N.V./ NL0015285941 /

2024-04-24 8:01:29 AM	Chg. +0.1250	Volume	Bid1:20:06 PM	Ask1:20:06 PM	High	Low
9.6300EUR	+1.32%	0 Turnover: 0.0000	9.6050Bid Size: 1,000	9.8100Ask Size: 1,000	9.6300	9.6300

GlobeNewswire 03-21 Immatics Announces Full Year 2023 Financial Results and Corporate Update

Newsfile Corp 02-15 Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

GlobeNewswire 01-18 Immatics Announces Pricing of $175 Million Public Offering

GlobeNewswire 01-17 Immatics Announces Proposed Public Offering

GlobeNewswire 01-09 PRISM MarketView Honors National Biotechnology Month with a Spotlight on Emerging Biotech Innovators

GlobeNewswire 2023-11-30 Levicept Appoints Eliot Forster as CEO

GlobeNewswire 2023-11-14 Immatics Announces Third Quarter 2023 Financial Results and Business Update

GlobeNewswire 2023-11-08 Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targ...

GlobeNewswire 2023-10-24 Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA20...

GlobeNewswire 2023-09-11 Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology...

GlobeNewswire 2023-08-17 Immatics Announces Second Quarter 2023 Financial Results and Business Update

GlobeNewswire 2022-01-11 Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to Pr...

Newsfile Corp 2021-12-14 Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, ...

GlobeNewswire 2021-12-14 Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific P...

GlobeNewswire 2021-11-16 Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 2021-11-09 Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 P...

GlobeNewswire 2021-11-01 Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immu...

GlobeNewswire 2021-08-10 Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire 2021-05-26 Immatics Announces Changes to its Board of Directors

GlobeNewswire 2021-05-18 Immatics Announces First Quarter 2021 Financial Results and Business Update

GlobeNewswire 2021-05-11 Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRA...

GlobeNewswire 2021-03-30 Immatics Announces Full Year 2020 Financial Results and Corporate Update

GlobeNewswire 2021-03-17 Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

GlobeNewswire 2020-12-22 Global Kinetics appoints Thomas Ulmer as Chief Financial Officer

GlobeNewswire 2020-12-02 Immatics Announces Third Quarter 2020 Financial Results and Business Update

IMMATICS N.V./ NL0015285941 /

If you wish to receive reply to your feedback, please provide your email address.